Literature DB >> 19258188

Hereditary colorectal cancer: MYH-associated polyposis and other newly identified disorders.

Noralane M Lindor1.   

Abstract

Historically, discussions of familial adenomatous polyposis and hereditary non-polyposis colon cancer have dominated lectures and writings on hereditary predisposition to colorectal cancer. In the last decade, the subject has grown well beyond the two entities. In this paper, five topics relevant to genetic risk assessment for colorectal cancer are reviewed. These include the autosomal recessive MYH-associated polyposis, hyperplastic polyposis and serrated pathway syndrome, the association of autosomal dominant juvenile polyposis with hereditary hemorrhagic telangiectasia, familial colorectal cancer type X, and the syndrome of biallelic DNA mismatch repair gene mutations. Knowledge of these entities may assist clinicians to recognize and manage cases that do not fit into the more common syndromes of colorectal cancer predisposition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258188     DOI: 10.1016/j.bpg.2008.11.013

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  13 in total

1.  Familial colorectal cancer type X syndrome: two distinct molecular entities?

Authors:  Inês Francisco; Cristina Albuquerque; Pedro Lage; Hélio Belo; Inês Vitoriano; Bruno Filipe; Isabel Claro; Sara Ferreira; Paula Rodrigues; Paula Chaves; Carlos Nobre Leitão; António Dias Pereira
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

2.  Ser 524 is a phosphorylation site in MUTYH and Ser 524 mutations alter 8-oxoguanine (OG): a mismatch recognition.

Authors:  Sucharita Kundu; Megan K Brinkmeyer; Richard A Eigenheer; Sheila S David
Journal:  DNA Repair (Amst)       Date:  2010-08-17

3.  AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome.

Authors:  Monica L Marvin; Serina M Mazzoni; Casey M Herron; Sean Edwards; Stephen B Gruber; Elizabeth M Petty
Journal:  Am J Med Genet A       Date:  2011-03-17       Impact factor: 2.802

4.  The genetic basis of colorectal cancer in a population-based incident cohort with a high rate of familial disease.

Authors:  M O Woods; H B Younghusband; P S Parfrey; S Gallinger; J McLaughlin; E Dicks; S Stuckless; A Pollett; B Bapat; M Mrkonjic; A de la Chapelle; M Clendenning; S N Thibodeau; M Simms; A Dohey; P Williams; D Robb; C Searle; J S Green; R C Green
Journal:  Gut       Date:  2010-08-03       Impact factor: 23.059

5.  Genetic biomarkers for neoplastic colorectal cancer in peripheral lymphocytes.

Authors:  Mirela Ionescu; Mihai Ciocirlan; Cristina Ionescu; Gabriel Becheanu; Serban Gologan; Adriana Teiusanu; Tudor Arbanas; Diculescu Mircea
Journal:  Maedica (Buchar)       Date:  2011-04

6.  Colorectal cancer in a monoallelic MYH mutation carrier.

Authors:  Racha Khalaf; Christopher Jones; Warren Strutt; Paul Williamson
Journal:  J Gastrointest Surg       Date:  2013-04-27       Impact factor: 3.452

7.  Ingredients for success: a familial cancer clinic in an oncology practice setting.

Authors:  Paul R Duncan; James T Lin
Journal:  J Oncol Pract       Date:  2011-01       Impact factor: 3.840

Review 8.  Serrated polyposis syndrome: molecular, pathological and clinical aspects.

Authors:  Carla Guarinos; Cristina Sánchez-Fortún; María Rodríguez-Soler; Cristina Alenda; Artemio Payá; Rodrigo Jover
Journal:  World J Gastroenterol       Date:  2012-05-28       Impact factor: 5.742

9.  Results from an American Society of Colon and Rectal Surgeons survey on the management of young-onset colorectal cancer.

Authors:  S K Warrier; M F Kalady; R P Kiran; J M Church
Journal:  Tech Coloproctol       Date:  2013-07-27       Impact factor: 3.781

Review 10.  MYH polyposis syndrome: clinical findings, genetics issues and management.

Authors:  M Sereno; M Merino; M López-Gómez; C Gómez-Raposo; F Zambrana Tébar; J Moreno Rubio; J Espinós; S Martín-Algarra; E Casado Sáenz
Journal:  Clin Transl Oncol       Date:  2014-03-19       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.